SCHEMBL3576127

SCHEMBL3576127

CCNc1ncc(Cl)cc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 2/20 0.48
CHRNA7 P36544 3/20 0.45
HCAR3 P49019 1/20 0.41
PGK1 P00558 3/20 0.38
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
GABRA4 P48169 1/20 0.38
GABRE P78334 1/20 0.38
GABRA6 Q16445 1/20 0.38
GABRG1 Q8N1C3 1/20 0.38
GABRG3 Q99928 1/20 0.38
GABRQ Q9UN88 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9251146 0.86 CHRNA7 (0.46) DHODHCHRNA7HCAR3KDM4EALDH1A1
SCHEMBL9261169 0.83 DHODH (0.47) DHODHCHRNA7ALDH1A1KMT2AHSD17B10
SCHEMBL3571511 0.82 DHODH (0.42) DHODHCHRNA7HCAR3GABRPGABRD
SCHEMBL15635868 0.82 DHODH (0.42) DHODHCHRNA7KDM4EALDH1A1MEN1
SCHEMBL1397722 0.81 DHODH (0.51) DHODHCHRNA7KDM4EALDH1A1SMN1; SMN2
SCHEMBL15635442 0.81 DHODH (0.46) DHODHCHRNA7ALDH1A1MEN1KMT2A
SCHEMBL3572839 0.81 HCAR3 (0.41) CHRNA7HCAR3GABRPGABRDGABRA1
SCHEMBL3576168 0.81 JAK2 (0.43) DHODHCHRNA7HCAR3GABRPGABRD
SCHEMBL15635184 0.80 DHODH (0.48) DHODHKDM4EALDH1A1HSD17B10TP53
SCHEMBL15635615 0.80 DHODH (0.48) DHODHALDH1A1HSD17B10TP53MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984340-B1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-06-27 EP disclosed
CN-101379036-B Anthranilamide/2-amino-heteroarene carboxamide derivatives HOFFMANN LA ROCHE 2011-06-01 CN disclosed
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
CN-101379036-A Anthranilamide/2-amino-heteroarene carboxamide derivatives HOFFMANN LA ROCHE (CH) 2009-03-04 CN disclosed
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds AADAT, AAAS, AADAC DHODH 2442/4885CHRNA7 626/4885HCAR3 990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.